Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 2.9 %

Shares of NYSE:BTX opened at $6.74 on Friday. The company has a market cap of $396.49 million, a price-to-earnings ratio of -2.97 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $6.35 and a 12 month high of $8.31. The company has a 50-day moving average price of $3.38 and a 200 day moving average price of $1.72.

Brooklyn ImmunoTherapeutics Announces Dividend

The business also recently announced a monthly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, March 14th will be given a dividend of $0.0862 per share. This represents a $1.03 annualized dividend and a dividend yield of 15.34%. The ex-dividend date is Friday, March 14th. Brooklyn ImmunoTherapeutics’s dividend payout ratio is currently -38.33%.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.